<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Acta Virol.</journal-id>
<journal-title>Acta Virologica</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Acta Virol.</abbrev-journal-title>
<issn pub-type="epub">1336-2305</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">12464</article-id>
<article-id pub-id-type="doi">10.3389/av.2023.12464</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Science archive</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Virtual screening and molecular dynamics simulation to identify potential SARS-CoV-2 3CL<sup>pro</sup> inhibitors from a natural product compounds library</article-title>
<alt-title alt-title-type="left-running-head">Gan et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/av.2023.12464">10.3389/av.2023.12464</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gan</surname>
<given-names>Chunchun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jia</surname>
<given-names>Xiaopu</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fan</surname>
<given-names>Shuai</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Shuqing</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jing</surname>
<given-names>Weikai</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wei</surname>
<given-names>Xiaopeng</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2538103/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>School of Medicine</institution>, <institution>Quzhou College of Technology</institution>, <addr-line>Quzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics</institution>, <institution>School of Pharmacy</institution>, <institution>Tianjin Medical University</institution>, <addr-line>Tianjin</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/819735/overview">Katarina Polcicova</ext-link>, Slovak Academy of Sciences, Slovakia</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Xiaopeng Wei, <email>weixiaopeng@tmu.edu.cn</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>67</volume>
<elocation-id>12464</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>03</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>11</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Gan, Jia, Fan, Wang, Jing and Wei.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Gan, Jia, Fan, Wang, Jing and Wei</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Based on the crystal structure of the 3C-like protease/Nsp5 (PDB ID 6W63), virtual hits were screened from a natural product compounds database&#x2014;containing 407270 natural products&#x2014;by using the high-throughput virtual screening (HTVS) module of Discovery Studio software, and then filtering by &#x201c;Lipinski&#x2019;s rule of five&#x201d; from the top 20 virtual hits. Two star-hits were selected by CDOCKER results and the protein-ligand interactions with the 3CL<sup>pro</sup> were analyzed. Finally, a 100 ns molecular dynamics simulation was carried out to verify the stability of the receptor-ligand complexes. We screened potent broad-spectrum non-covalent inhibitors that could bind to the SARS-CoV-2 3CL<sup>pro</sup> active binding site from the natural product compounds library through HTVS and molecular dynamics simulations methods. The LibDock scores and -CDOCKER energy value of the star-hits were higher than the original ligands (X77) bound to 3CL<sup>pro</sup>. <bold>CNP0348829</bold> and <bold>CNP0474002</bold>, as star-hits, can bind stably to the active site of 3CL<sup>pro</sup>, which are promising candidate compounds for the treatment of SARS-CoV-2 and provide a theoretical basis for the development of antiviral drugs. The results of the present study may be useful in the prevention and therapeutic perspectives of COVID-19. However, further <italic>in vitro</italic> and <italic>in vivo</italic> validation tests are required in the future.</p>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>3CL<sup>pro</sup>
</kwd>
<kwd>natural product compounds</kwd>
<kwd>virtual screening</kwd>
<kwd>molecular docking</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>In December 2019, an outbreak of a severe respiratory disease occurred in Wuhan, Hubei Province, China. On 11 February 2020, the World Health Organization announced that the new coronavirus pneumonia was named &#x201c;COVID-19&#x201d; (<xref ref-type="bibr" rid="B35">World Health Organization, 2022</xref>). The International Committee on Classification of Viruses has named the new coronavirus &#x201c;SARS-CoV-2&#x201d; (<xref ref-type="bibr" rid="B32">Wang et al., 2020</xref>). It is a zoonotic pathogen belonging to the genus &#x3b2;-coronavirus (&#x3b2;-CoV) of the Coronaviridae subfamily of ortho-coronaviruses. The virus initially attacks the respiratory system and causes flu-like symptoms such as cough and fever, and in severe cases, patients may develop acute respiratory distress syndrome and respiratory failure (<xref ref-type="bibr" rid="B25">Sahebnasagh et al., 2020</xref>). In addition, novel coronavirus pneumonia can cause systemic inflammation and acute cardiac damage, leading to arrhythmias, heart failure, and multi-organ dysfunction in critically ill patients (<xref ref-type="bibr" rid="B32">Wang et al., 2020</xref>). As of December 2022, over 645 million confirmed cases, and over 6.6 million deaths, have been reported globally.<xref ref-type="fn" rid="fn1">
<sup>1</sup>
</xref>
</p>
<p>Nsp5, sometimes referred to as 3C-like protease (3CL<sup>pro</sup>) or the major protease, is a cysteine protease that breaks down polyproteins at 11 different locations to produce mature, functional proteins. Viral replication depends on 3CL<sup>pro</sup>, the inhibition of which limits the synthesis of key enzymes for replication like RNA-dependent RNA polymerase (<xref ref-type="bibr" rid="B30">Ullrich and Nitsche, 2020</xref>). Furthermore, as the 3CL<sup>pro</sup> and spike proteins are independent proteins encoded in different parts of the viral genome, the 3CL<sup>pro</sup> inhibitor&#x2019;s antiviral activity would probably not be impacted and it does not trigger mutations in the spike protein, which frequently occur in SARS-CoV-2 variations. Consequently, 3CL<sup>pro</sup> is a potential target for COVID-19 treatment using small-molecule oral therapies (<xref ref-type="bibr" rid="B39">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="B31">Unoh et al., 2022</xref>).</p>
<p>Natural products have always played a crucial role in drug development against various diseases. Therefore, traditional herbs from diverse geographical locations and various habitats could be considered as potential sources of new drugs for the treatment of viral infections, including those caused by SARS-CoVs and its emergent mutants. After the outbreak of novel coronavirus pneumonia, the National Health Commission of People&#x2019;s Republic of China promptly issued the &#x201c;Treatment Protocol for COVID-19,&#x201d; which has been updated to the ninth edition on a trial basis as of 15 March 2022. In the course of COVID-19 treatment, Traditional Chinese Medicine (TCM) including &#x201c;XueBiJing injection,&#x201d; &#x201c;TanReQing injection,&#x201d; &#x201c;JinHuaQingGan granule,&#x201d; &#x201c;XiYanPing injection&#x201d; and others participated in the whole treatment process and played a significant role (<xref ref-type="bibr" rid="B38">Zhuang et al., 2020</xref>). On 31 March 2022, the World Health Organization<xref ref-type="fn" rid="fn2">
<sup>2</sup>
</xref> published a report stating that &#x201c;TCM can effectively treat COVID-19, reduce the conversion of mild and common cases to severe disease, shorten the time of virus clearance, and improve the clinical prognosis of mild and common patients&#x201d; (<xref ref-type="bibr" rid="B34">WHO Team, 2022</xref>), which shows that natural products play a very important role in the prevention and treatment of COVID-19. Therefore, screening for candidates from a natural products library<xref ref-type="fn" rid="fn3">
<sup>3</sup>
</xref> is a potential strategy for antiviral drug development.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>High-throughput virtual screening</title>
<p>The structures of compounds were obtained from the Coconut database,<xref ref-type="fn" rid="fn3">
<sup>3</sup>
</xref> and the crystal structure of 3CL<sup>pro</sup> (6W63) was downloaded from the PDB database.<xref ref-type="fn" rid="fn4">
<sup>4</sup>
</xref> Discovery Studio software (version 4.0, Biovea Inc., Omaha, NE, USA) was applied to molecule docking. The compounds of the Coconut database were prepared using the &#x201c;Prepare Ligands&#x201d; module. After removing crystallographic water molecules and ligands, the &#x201c;Prepare Protein&#x201d; module was used to remove the conformation of the target protein and to fill the incomplete amino acid residues. Then, the virtual screening was performed in the &#x201c;LibDock&#x201d; module, which is a virtual high-throughput algorithm for docking ligands into the receptor active sites. CDOCKER, as an implementation of a CHARMm based docking tool using a rigid receptor, was used to further molecular docking. Ligand conformations were aligned to receptor interaction sites (hotspots) and the best scoring poses were reported (<xref ref-type="bibr" rid="B36">Wu et al., 2003</xref>; <xref ref-type="bibr" rid="B20">Mohan et al., 2015</xref>).</p>
</sec>
<sec id="s2-2">
<title>Molecular dynamics (MD) simulation</title>
<p>In order to verify the time-dependent stability of ligand-receptor complexes, Desmond_maestro 2020.4 with OPLS_2005 force filed<xref ref-type="fn" rid="fn5">
<sup>5</sup>
</xref> tools was used to perform a 100-ns molecular dynamics simulation on the receptor-ligand complexes obtained by virtual screening (<xref ref-type="bibr" rid="B21">Okimoto et al., 2009</xref>; <xref ref-type="bibr" rid="B9">Gahlawat et al., 2020</xref>). Firstly, in an orthorhombic box, the system was solvated with the SPC water model and neutralized by Cl<sup>&#x2212;</sup> or Na<sup>&#x2b;</sup> ions. The system energy was minimized at T &#x3d; 0&#xa0;K while the force field could be used to regulate the structure of the molecules, followed by ensuring the system stability by the equilibration processes and heating. Subsequently, MD simulation was carried out under periodic boundary conditions and NPT ensemble at T &#x3d; 300&#xa0;K and 1&#xa0;atm pressure using a Nose&#x2013;Hoover thermostat and Martyna&#x2013;Tuckerman&#x2013;Klein barostat (<xref ref-type="bibr" rid="B17">Li et al., 2019</xref>; <xref ref-type="bibr" rid="B28">Srivastava et al., 2021</xref>). The parameters, such as root-mean-square-deviation (RMSD) for the receptor and ligand, root-mean-square-fluctuation (RMSF) of the protein and ligand, or numbers of hydrogen bonds, were calculated to evaluate the stability of receptor-ligand complexes. The change in conformation can be analyzed by the change in RMSD, showing whether the equilibrium is reached during the simulation. When the shift between the specific frame and the reference frame is 1&#x2013;3&#xa0;&#xc5;, it can be considered that the shift of the specific frame is not much different from the reference frame. However, it indicates that a larger conformational change has occurred during the simulation when the shift change is apparent. The backbone RMSD curve represents the RMSD of the protein backbone over time. Lig_fit_Prot curve represents the RMSD of the ligand when the protein-ligand complex is first aligned to the protein backbone and then the RMSD of the heavy atom is measured. It is likely that the ligand has diffused away from its initial binding site if a value significantly larger than the RMSD of the protein is observed. The lig_fit_lig curve represents the RMSD of the ligand when the ligand is aligned in its reference conformation which is used to measure the internal fluctuations of the ligand atoms.</p>
</sec>
<sec id="s2-3">
<title>ADMET properties prediction</title>
<p>AdmetSAR2<xref ref-type="fn" rid="fn6">
<sup>6</sup>
</xref> is a website which allows user to search for ADME/T (Absorption, Distribution, Metabolism, Excretion, and Toxicity including Ames toxicity, carcinogenic properties, acute oral toxicity, and rat acute toxicity) properties profiling by name, CASRN, and similarity search (<xref ref-type="bibr" rid="B37">Yang et al., 2019</xref>). At the same time, Swiss-ADME online web server<xref ref-type="fn" rid="fn7">
<sup>7</sup>
</xref> was used to predict physicochemical properties, water solubility, pharmacokinetics, lipophilicity, drug-likeness drug-like nature (according to drug-likeness rules: Lipinski, Ghose, Veber, Egan, and Muegge), and medicinal chemistry friendliness (PAINS, Brenk, Lead-likeness, Synthetic accessibility) (<xref ref-type="bibr" rid="B4">Daina et al., 2017</xref>).</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and discussion</title>
<sec id="s3-1">
<title>Molecular docking results and analysis</title>
<p>With the rapid development of various computer methods such as molecular modeling, molecular docking, and molecular dynamics simulations, modern computer tools provide new strategies to explore the scientific basis of TCM (<xref ref-type="bibr" rid="B13">Jiao et al., 2021</xref>). Molecular docking is an established <italic>in silico</italic> structure-based method widely used in drug discovery. Docking enables the identification of novel compounds of therapeutic interest, predicting ligand-target interactions at the atom level, or delineating structure-activity relationships (SAR), without knowing <italic>a priori</italic> the chemical structure of other target modulators (<xref ref-type="bibr" rid="B23">Pinzi and Rastelli, 2019</xref>).</p>
<p>It has been shown that structural domain III (residues 201-301) of the 3CL<sup>pro</sup> has catalytic activity (<xref ref-type="bibr" rid="B29">Tahir Ul Qamar et al., 2020</xref>). X77 can bind at the active site to inhibit the catalytic activity of the 3CL<sup>pro</sup> (<xref ref-type="bibr" rid="B9">Gahlawat et al., 2020</xref>). The interaction diagram of inhibitor X77 bound to 3CL<sup>pro</sup> is shown in <xref ref-type="fig" rid="F1">Figure 1A</xref>. X77 bound to 3CL<sup>pro</sup> by two hydrogen bonds between residues GLY143 and GLU166, Pi-Sulfur interaction with residues MET49, amide-Pi stacked with residues LEU141, and other hydrophobic interactions. Very interestingly, as shown in the middle part in <xref ref-type="fig" rid="F1">Figure 1A</xref>, X77 is docked into the active pocket by an &#x201c;X&#x201d; shape.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Molecular docking diagram of COVID-19 3CL<sup>pro</sup> bound to X77 and star-hits, generated by Discovery Studio software. <bold>(A)</bold> Interaction diagram of 3CL<sup>pro</sup> bound to non-covalent inhibitor X77. <bold>(B, C)</bold> Action modes of <bold>CNP0348829</bold> and <bold>CNP0474002</bold> with target 3CL<sup>pro</sup> respectively.</p>
</caption>
<graphic xlink:href="av-67-12464-g001.tif"/>
</fig>
<p>The top 20 virtual hits with different structural skeletons are listed in <xref ref-type="table" rid="T1">Table 1</xref>. The binding affinities of all compounds were assessed through LibDock Scores and -CDOCKER energy value. According to the LibDock score results, all compounds had apparent interactions with the target protein. The top 20 virtual hits showed stronger interactions with 3CL<sup>pro</sup> than the original inhibitor X77. Two -CDOCKER interaction energy values of 38.6734 and 35.6722&#xa0;kcal/mol, compared to that of X77 (-CDOCKER_ENERGY &#x3d; 30.4747), were calculated, indicating that <bold>CNP0348829</bold> and <bold>CNP0474002</bold> are promising candidate compounds for the treatment of SARS-CoV-2. The ADMET property predictions of the virtual hits were demonstrated in <xref ref-type="table" rid="T2">Tables 2</xref>, <xref ref-type="table" rid="T3">3</xref> in order to investigate how molecules can access the target site of 3CL<sup>pro</sup> after entering the bloodstream. This analysis is also crucial for analyzing the efficacy of molecules (<xref ref-type="bibr" rid="B7">Fadaka et al., 2022</xref>). All parameters were within the Lipinski&#x2019;s rule of five (ROF) cut-off range for the test compounds except <bold>CNP0465303</bold> and <bold>CNP0447420</bold> and present no bystander toxicity effects, since managing toxicity is the main task in developing new medications. Ames toxicity, carcinogenic properties, and rat acute toxicity which are important parameters of drug safety, were predicted in the current investigation. According to the results, most of the compounds showed no Ames toxicity, no carcinogenic properties, and low toxicity, meaning they are safe when used as drugs (<xref ref-type="bibr" rid="B8">Fadaka et al., 2021</xref>; <xref ref-type="bibr" rid="B7">2022</xref>). The ideal drug molecules fall under such criteria as molecular weight (&#x3c;500&#xa0;g/mol), MlogP values (&#x2264;4.5), rotatable bonds (&#x2264;10), HB acceptors (&#x3c;10), and number of HB donors (&#x3c;5) (<xref ref-type="bibr" rid="B18">Lipinski, 2004</xref>). We screened out two star-hits based on ROF, while others were eliminated because of the molecular weight or -CDOCKER_ENERGY values.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The LibDOCK scores and CDOCKER_ENERGY of top 20 virtual hits.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Coconut ID</th>
<th align="left">Structure</th>
<th align="left">LibDOCK scores</th>
<th align="left">-CDOCKER_ENERGY (kcal/mol)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">CNP0465303</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx1.tif"/>
</td>
<td align="left">188.883</td>
<td align="left">&#x2212;32.3854</td>
</tr>
<tr>
<td align="left">CNP0455361</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx2.tif"/>
</td>
<td align="left">183.594</td>
<td align="left">&#x2212;12.7831</td>
</tr>
<tr>
<td align="left">CNP0457047</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx3.tif"/>
</td>
<td align="left">178.976</td>
<td align="left">14.2185</td>
</tr>
<tr>
<td align="left">CNP0139709</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx4.tif"/>
</td>
<td align="left">167.513</td>
<td align="left">26.1017</td>
</tr>
<tr>
<td align="left">CNP0458104</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx5.tif"/>
</td>
<td align="left">166.682</td>
<td align="left">&#x2212;13.015</td>
</tr>
<tr>
<td align="left">CNP0478503</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx6.tif"/>
</td>
<td align="left">159.788</td>
<td align="left">&#x2212;7.49867</td>
</tr>
<tr>
<td align="left">CNP0475158</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx7.tif"/>
</td>
<td align="left">156.399</td>
<td align="left">9.84003</td>
</tr>
<tr>
<td align="left">CNP0447420</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx8.tif"/>
</td>
<td align="left">155.407</td>
<td align="left">23.1654</td>
</tr>
<tr>
<td align="left">CNP0457847</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx9.tif"/>
</td>
<td align="left">154.03</td>
<td align="left">&#x2212;13.7951</td>
</tr>
<tr>
<td align="left">CNP0478727</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx10.tif"/>
</td>
<td align="left">150.303</td>
<td align="left">&#x2212;34.5301</td>
</tr>
<tr>
<td align="left">CNP0446191</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx11.tif"/>
</td>
<td align="left">150.107</td>
<td align="left">24.5206</td>
</tr>
<tr>
<td align="left">CNP0474861</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx12.tif"/>
</td>
<td align="left">143.167</td>
<td align="left">&#x2212;52.9031</td>
</tr>
<tr>
<td align="left">
<bold>&#x2605;CNP0348829</bold>
</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx13.tif"/>
</td>
<td align="left">
<bold>142.061</bold>
</td>
<td align="left">
<bold>38.6734</bold>
</td>
</tr>
<tr>
<td align="left">CNP0475639</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx14.tif"/>
</td>
<td align="left">140.811</td>
<td align="left">&#x2212;6.46299</td>
</tr>
<tr>
<td align="left">CNP0475126</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx15.tif"/>
</td>
<td align="left">138.716</td>
<td align="left">19.2972</td>
</tr>
<tr>
<td align="left">
<bold>&#x2605;CNP0474002</bold>
</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx16.tif"/>
</td>
<td align="left">
<bold>138.328</bold>
</td>
<td align="left">
<bold>35.6722</bold>
</td>
</tr>
<tr>
<td align="left">CNP0474130</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx17.tif"/>
</td>
<td align="left">138.274</td>
<td align="left">4.57313</td>
</tr>
<tr>
<td align="left">CNP0458286</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx18.tif"/>
</td>
<td align="left">137.822</td>
<td align="left">6.98237</td>
</tr>
<tr>
<td align="left">CNP0474134</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx19.tif"/>
</td>
<td align="left">137.745</td>
<td align="left">13.4454</td>
</tr>
<tr>
<td align="left">CNP0436312</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx20.tif"/>
</td>
<td align="left">136.109</td>
<td align="left">&#x2212;19.9438</td>
</tr>
<tr>
<td align="left">Inhibitor (X77)</td>
<td align="left">
<inline-graphic xlink:href="AV_av-2023-12464_wc_tfx21.tif"/>
</td>
<td align="left">123.888</td>
<td align="left">30.4747</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>&#x2a;Screened star-hit compounds are highlighted with bold font and with the star symbol.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>ADME properties of top 20 virtual hits.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Compound<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref>
</th>
<th align="left">Formula</th>
<th align="left">MW<xref ref-type="table-fn" rid="Tfn2">
<sup>b</sup>
</xref>
</th>
<th align="left">NRB<xref ref-type="table-fn" rid="Tfn3">
<sup>c</sup>
</xref>
</th>
<th align="left">NBD<xref ref-type="table-fn" rid="Tfn4">
<sup>d</sup>
</xref>
</th>
<th align="left">NBA<xref ref-type="table-fn" rid="Tfn5">
<sup>e</sup>
</xref>
</th>
<th align="left">MLogP<xref ref-type="table-fn" rid="Tfn6">
<sup>f</sup>
</xref>
</th>
<th align="left">GI absorption<xref ref-type="table-fn" rid="Tfn7">
<sup>g</sup>
</xref>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">CNP0465303</td>
<td align="left">C<sub>49</sub>H<sub>48</sub>N<sub>2</sub>O<sub>7</sub>
</td>
<td align="left">776.915</td>
<td align="left">10</td>
<td align="left">4</td>
<td align="left">9</td>
<td align="left">8.082</td>
<td align="left">Low</td>
</tr>
<tr>
<td align="left">CNP0455361</td>
<td align="left">C<sub>50</sub>H<sub>68</sub>N<sub>2</sub>O<sub>6</sub>
</td>
<td align="left">792.510</td>
<td align="left">9</td>
<td align="left">3</td>
<td align="left">7</td>
<td align="left">4.406</td>
<td align="left">Low</td>
</tr>
<tr>
<td align="left">CNP0457047</td>
<td align="left">C<sub>35</sub>H<sub>37</sub>NO<sub>7</sub>
</td>
<td align="left">583.671</td>
<td align="left">10</td>
<td align="left">4</td>
<td align="left">7</td>
<td align="left">6.033</td>
<td align="left">Low</td>
</tr>
<tr>
<td align="left">CNP0139709</td>
<td align="left">C<sub>30</sub>H<sub>42</sub>O<sub>7</sub>
</td>
<td align="left">514.65</td>
<td align="left">10</td>
<td align="left">3</td>
<td align="left">7</td>
<td align="left">5.769</td>
<td align="left">High</td>
</tr>
<tr>
<td align="left">CNP0458104</td>
<td align="left">C<sub>30</sub>H<sub>37</sub>N<sub>1</sub>O<sub>5</sub>
</td>
<td align="left">491.618</td>
<td align="left">10</td>
<td align="left">1</td>
<td align="left">6</td>
<td align="left">4.642</td>
<td align="left">High</td>
</tr>
<tr>
<td align="left">CNP0478503</td>
<td align="left">C<sub>25</sub>H<sub>30</sub>N<sub>2</sub>O<sub>4</sub>
</td>
<td align="left">423.525</td>
<td align="left">9</td>
<td align="left">3</td>
<td align="left">5</td>
<td align="left">1.499</td>
<td align="left">High</td>
</tr>
<tr>
<td align="left">CNP0475158</td>
<td align="left">C<sub>27</sub>H<sub>45</sub>N<sub>3</sub>O<sub>5</sub>
</td>
<td align="left">491.663</td>
<td align="left">10</td>
<td align="left">4</td>
<td align="left">6</td>
<td align="left">1.276</td>
<td align="left">Low</td>
</tr>
<tr>
<td align="left">CNP0447420</td>
<td align="left">C<sub>23</sub>H<sub>25</sub>N<sub>5</sub>O<sub>5</sub>
</td>
<td align="left">567.628</td>
<td align="left">6</td>
<td align="left">1</td>
<td align="left">8</td>
<td align="left">3.745</td>
<td align="left">Low</td>
</tr>
<tr>
<td align="left">CNP0457847</td>
<td align="left">C<sub>33</sub>H<sub>49</sub>N<sub>1</sub>O<sub>6</sub>
</td>
<td align="left">555.745</td>
<td align="left">8</td>
<td align="left">5</td>
<td align="left">6</td>
<td align="left">4.94</td>
<td align="left">Low</td>
</tr>
<tr>
<td align="left">CNP0478727</td>
<td align="left">C<sub>40</sub>H<sub>42</sub>N<sub>4</sub>O<sub>5</sub>
</td>
<td align="left">659.793</td>
<td align="left">9</td>
<td align="left">4</td>
<td align="left">8</td>
<td align="left">3.544</td>
<td align="left">Low</td>
</tr>
<tr>
<td align="left">CNP0446191</td>
<td align="left">C<sub>22</sub>H<sub>30</sub>N<sub>4</sub>O<sub>5</sub>
</td>
<td align="left">430.497</td>
<td align="left">7</td>
<td align="left">6</td>
<td align="left">6</td>
<td align="left">&#x2212;0.859</td>
<td align="left">Low</td>
</tr>
<tr>
<td align="left">CNP0474861</td>
<td align="left">C<sub>29</sub>H<sub>36</sub>O<sub>9</sub>
</td>
<td align="left">528.591</td>
<td align="left">3</td>
<td align="left">2</td>
<td align="left">9</td>
<td align="left">1.393</td>
<td align="left">Low</td>
</tr>
<tr>
<td align="left">&#x2605;<bold>CNP0348829</bold>
</td>
<td align="left">C<sub>24</sub>H<sub>27</sub>N<sub>1</sub>O<sub>5</sub>
</td>
<td align="left">409.475</td>
<td align="left">8</td>
<td align="left">2</td>
<td align="left">5</td>
<td align="left">3.742</td>
<td align="left">High</td>
</tr>
<tr>
<td align="left">CNP0475639</td>
<td align="left">C<sub>24</sub>H<sub>45</sub>N<sub>3</sub>O<sub>3</sub>
</td>
<td align="left">425.648</td>
<td align="left">6</td>
<td align="left">5</td>
<td align="left">4</td>
<td align="left">&#x2212;1.863</td>
<td align="left">Low</td>
</tr>
<tr>
<td align="left">CNP0475126</td>
<td align="left">C<sub>22</sub>H<sub>31</sub>FN<sub>4</sub>O<sub>3</sub>
</td>
<td align="left">418.505</td>
<td align="left">6</td>
<td align="left">3</td>
<td align="left">5</td>
<td align="left">&#x2212;0.069</td>
<td align="left">High</td>
</tr>
<tr>
<td align="left">&#x2605;<bold>CNP0474002</bold>
</td>
<td align="left">C<sub>24</sub>H<sub>33</sub>FN<sub>4</sub>O<sub>5</sub>
</td>
<td align="left">476.541</td>
<td align="left">8</td>
<td align="left">2</td>
<td align="left">5</td>
<td align="left">1.164</td>
<td align="left">High</td>
</tr>
<tr>
<td align="left">CNP0474130</td>
<td align="left">C<sub>23</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>
</td>
<td align="left">479.515</td>
<td align="left">5</td>
<td align="left">3</td>
<td align="left">4</td>
<td align="left">3.811</td>
<td align="left">High</td>
</tr>
<tr>
<td align="left">CNP0458286</td>
<td align="left">C<sub>19</sub>H<sub>19</sub>N<sub>5</sub>O<sub>4</sub>
</td>
<td align="left">381.385</td>
<td align="left">6</td>
<td align="left">2</td>
<td align="left">8</td>
<td align="left">0.419</td>
<td align="left">High</td>
</tr>
<tr>
<td align="left">CNP0474134</td>
<td align="left">C<sub>20</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>S</td>
<td align="left">416.54</td>
<td align="left">9</td>
<td align="left">4</td>
<td align="left">5</td>
<td align="left">0.3</td>
<td align="left">High</td>
</tr>
<tr>
<td align="left">CNP0436312</td>
<td align="left">C<sub>29</sub>H<sub>44</sub>O<sub>8</sub>
</td>
<td align="left">520.655</td>
<td align="left">10</td>
<td align="left">0</td>
<td align="left">8</td>
<td align="left">3.81</td>
<td align="left">High</td>
</tr>
<tr>
<td align="left">Inhibitor (X77)</td>
<td align="left">C<sub>27</sub>H<sub>33</sub>N<sub>5</sub>O<sub>2</sub>
</td>
<td align="left">459.583</td>
<td align="left">7</td>
<td align="left">2</td>
<td align="left">4</td>
<td align="left">3.886</td>
<td align="left">High</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn1">
<label>
<sup>a</sup>
</label>
<p>Compound ID from Coconut database.</p>
</fn>
<fn id="Tfn2">
<label>
<sup>b</sup>
</label>
<p>Molecular weight of the compounds (acceptable range: &#x2264;500&#xa0;g/mol).</p>
</fn>
<fn id="Tfn3">
<label>
<sup>c</sup>
</label>
<p>Number of rotatable bonds (acceptable range: &#x2264;10).</p>
</fn>
<fn id="Tfn4">
<label>
<sup>d</sup>
</label>
<p>Number of H-bond donors (acceptable range: &#x2264;5).</p>
</fn>
<fn id="Tfn5">
<label>
<sup>e</sup>
</label>
<p>Number of H-bond acceptors (acceptable range: &#x003c;&#x003d;10).</p>
</fn>
<fn id="Tfn6">
<label>
<sup>f</sup>
</label>
<p>MlogP: log P by the method of Moriguchi (acceptable range: 4.5).</p>
</fn>
<fn id="Tfn7">
<label>
<sup>g</sup>
</label>
<p>Gatrointestinal absorption.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Toxicity analysis of the top 20 virtual hits predicted by AdmetSAR2.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Compound</th>
<th align="left">Ames toxicity</th>
<th align="left">Carcinogens</th>
<th align="left">Acute oral toxicity log (1/(mol/kg))</th>
<th align="left">Rat acute toxicity</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">CNP0465303</td>
<td align="left">AT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.6938</td>
</tr>
<tr>
<td align="left">CNP0455361</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.9773</td>
</tr>
<tr>
<td align="left">CNP0457047</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.9038</td>
</tr>
<tr>
<td align="left">CNP0139709</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">3.2080</td>
</tr>
<tr>
<td align="left">CNP0458104</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.9703</td>
</tr>
<tr>
<td align="left">CNP0478503</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.6235</td>
</tr>
<tr>
<td align="left">CNP0475158</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.8388</td>
</tr>
<tr>
<td align="left">CNP0447420</td>
<td align="left">AT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.4641</td>
</tr>
<tr>
<td align="left">CNP0457847</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.9475</td>
</tr>
<tr>
<td align="left">CNP0478727</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.7368</td>
</tr>
<tr>
<td align="left">CNP0446191</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.3597</td>
</tr>
<tr>
<td align="left">CNP0474861</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.7944</td>
</tr>
<tr>
<td align="left">&#x2605;<bold>CNP0348829</bold>
</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.6326</td>
</tr>
<tr>
<td align="left">CNP0475639</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.5313</td>
</tr>
<tr>
<td align="left">CNP0475126</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.5391</td>
</tr>
<tr>
<td align="left">&#x2605;<bold>CNP0474002</bold>
</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.4915</td>
</tr>
<tr>
<td align="left">CNP0474130</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.7055</td>
</tr>
<tr>
<td align="left">CNP0458286</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.3477</td>
</tr>
<tr>
<td align="left">CNP0474134</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.4560</td>
</tr>
<tr>
<td align="left">CNP0436312</td>
<td align="left">NAT</td>
<td align="left">NC</td>
<td align="left">III</td>
<td align="left">2.3490</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Note: AT, Ames toxic; NAT, Non Ames toxic; NC, Non-carcinogenic; Category-III means (500&#xa0;mg/kg &#x3e; LD50 &#x3c; 5,000&#xa0;mg/kg).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Interaction diagrams of <bold>CNP0348829</bold> and <bold>CNP0474002</bold> bound to 3CL<sup>pro</sup> are shown in <xref ref-type="fig" rid="F1">Figures 1B, C</xref>. As seen in <xref ref-type="fig" rid="F1">Figure 1B</xref>, <bold>CNP0348829</bold> was stabilized by three strong hydrogen bond interactions between residues SER144, CYS145, and HIS163. In addition, the ring exhibited very strong Pi&#x2013;Pi stacked interactions with HIS41, Pi&#x2013;sulfur interaction with CYS44. <bold>CNP0474002</bold>-3CL<sup>pro</sup> bound to 3CL<sup>pro</sup> by hydrogen bond interactions between C&#x3d;O of amide with CYS145. The Pi&#x2013;alkyl stacked interactions between residues MET165 and 18-phenyl and X&#x2013;sulfur interaction with MET49 like <bold>CNP0348829</bold> were also observed (<xref ref-type="fig" rid="F1">Figure 1C</xref>; <xref ref-type="table" rid="T4">Table 4</xref>). Both <bold>CNP0348829</bold> and <bold>CNP0474002</bold> bound to the 3CL<sup>pro</sup> in a spreading conformation, <bold>CNP0474002</bold> was docked into the active pocket by an &#x201c;X&#x201d; shape, somewhat like X77.</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>The interaction of star hit compounds and X77 with 3CL<sup>pro</sup>.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Compound</th>
<th align="left">Key interaction</th>
<th align="left">No. of NBs</th>
<th align="left">Key residues</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<bold>CNP0348829</bold>
</td>
<td align="left">Hydrogen Bond, Pi-Pi Stacked, Pi-Sulfur, Pi-Alkyl</td>
<td align="left">3</td>
<td align="left">HIS163, CYS145, SER144</td>
</tr>
<tr>
<td align="left">
<bold>CNP0474002</bold>
</td>
<td align="left">Hydrogen Bond, Pi-Alkyl, Halogen, (Fluorine), X-Sulfur, Amid-Pi Stacked</td>
<td align="left">1</td>
<td align="left">CYS145, MET49, GLU166, MET165</td>
</tr>
<tr>
<td align="left">Inhibitor (X77)</td>
<td align="left">Hydrogen Bond, Pi-Sulfur, Amid-Pi Stacked, Pi-Alkyl</td>
<td align="left">2</td>
<td align="left">GLU166, LEU141, GLY143, MET49</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-2">
<title>Molecular dynamics simulation results and analysis</title>
<p>To verify the results of molecular docking, molecular dynamics simulations were introduced in this study. Molecular dynamics simulations can show the microscopic evolution of the system at the atomic level and visualize the mechanisms and patterns of experimental phenomena, which is a great advantage in studying the mechanism of ligand-receptor interaction (<xref ref-type="bibr" rid="B1">Adcock and McCammon, 2006</xref>).</p>
<p>The change in conformation can be analyzed by the value of RMSD, showing whether the equilibrium is reached during the simulation. When the position-shift between the specific frame and the reference frame is 1&#x2013;3&#xa0;&#xc5;, it can be considered that the position-shift of the specific frame is not much different from the reference frame. It indicates that a larger conformational change occurred during the simulation when the position-shift change is apparent. The backbone RMSD curve represents the RMSD of the protein backbone over time. Lig_fit_Prot curve represents the RMSD of the ligand when the protein-ligand complex is first aligned to the protein backbone and then the RMSD of the heavy atom is measured. It is likely that the ligand has shifted away from its initial binding site if the value is significantly larger than the RMSD of the protein. The lig_fit_lig curve represents the RMSD of the ligand when the ligand is aligned in its reference conformation which is used to measure the internal fluctuations of the ligand atoms.</p>
<p>The results of molecular dynamics simulations are shown in <xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F3">3</xref>. The major deviation is in RMSD-P, which shows the protein RMSD with a ligand in the active site. The compound <bold>CNP0348829</bold> showed initial light fluctuation in RMSD-L, at around 1 &#x00C5; and 3 &#x00C5;. However, it showed very strong fluctuations at 52 ns, mainly resulting from the change of conformation at the 12-phenyl, while remaining in the active site of the receptor and stabilized for the remaining period of time in the range of 3.5 &#x00C5; to 5.5 &#x00C5;. (<xref ref-type="fig" rid="F2">Figures 2A, C, D</xref>). Unlike <bold>CNP0348829</bold>, <bold>CNP0474002</bold> was stabilized in the range of 3 &#x00C5; to 5.5 &#x00C5; at all times under study (<xref ref-type="fig" rid="F3">Figure 3A</xref>). The major initial fluctuation in the 3CL<sup>pro</sup> was mainly due to C-terminal fluctuations, which was confirmed by the RMSF plot for the protein C (alpha) and backbone, where except for C-terminal, all other residues showed RMSF less than 2.5 &#x00C5;. Over the period of analysis, C-terminal exhibited RMSF up to 4.5 &#x00C5; (<xref ref-type="fig" rid="F2">Figures 2B</xref>, <xref ref-type="fig" rid="F3">3B</xref>). RMSF of the ligand with the protein and the ligand with initial conformation was very stable and was between 1.00 and 2.25 &#x00C5; and 0.25 to 1.25 &#x00C5;, respectively (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Protein interactions with the ligands were monitored throughout the simulation, and these interactions can be summarized and classified into four types: hydrogen bonds, hydrophobic interactions, ionic bonds, and water bridges. Among all interactions, hydrogen bonds play an important role in the overall dynamics simulation because of their greater influence on compound specificity, metabolic characteristics, and adsorption parameters (<xref ref-type="bibr" rid="B15">Kruth et al., 2005</xref>). The following amino acids, such as HIS41, CYS145, and GLU166 in <bold>CNP0474002</bold>-3CL<sup>pro</sup> complex, and CYS44, ASN142, GLY143, SER144, and GLU166 in <bold>CNP0348829</bold>-3CL<sup>pro</sup> complex, contribute greatly to the interaction between protein and ligand. These interactions were categorized by type and summarized as shown in <xref ref-type="fig" rid="F4">Figures 4A, B</xref>. The above analysis suggests that the ligand-receptor complexes were maintained well within a relatively stable range with small fluctuations throughout the molecular dynamic simulations, indicating that the binding modes of <bold>CNP0348829</bold>-3CL<sup>pro</sup> and <bold>CNP0474002</bold>-3CL<sup>pro</sup> complexes are stable during the molecular dynamics simulation.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>
<bold>(A)</bold> RMSD of protein backbone, Lig_fit_Prot and Lig_fit_Lig for <bold>CNP0348829</bold>-3CL<sup>pro</sup> complex; <bold>(B)</bold> RMSF of protein C(alpha) and backbone; <bold>(C)</bold> RMSF of <bold>CNP0348829</bold>; <bold>(D)</bold> The 2D structure of <bold>CNP0348829</bold>.</p>
</caption>
<graphic xlink:href="av-67-12464-g002.tif"/>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>
<bold>(A)</bold> RMSD of protein backbone, Lig_fit_Prot and Lig_fit_Lig for <bold>CNP0474002</bold>-3CL<sup>pro</sup> complex; <bold>(B)</bold> RMSF of protein C(alpha) and backbone; <bold>(C)</bold> RMSF of <bold>CNP0474002</bold>; <bold>(D)</bold> The 2D structure of <bold>CNP0474002</bold>.</p>
</caption>
<graphic xlink:href="av-67-12464-g003.tif"/>
</fig>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Observed <bold>CNP0474002</bold>-3CL<sup>pro</sup> and <bold>CNP0348829</bold>-3CL<sup>pro</sup> complexes contacts during the 100 ns MD simulation. Interactions include: hydrogen bonds, hydrophobic, and water bridges. Letter codes indicate <bold>CNP0474002 (A)</bold>, <bold>CNP0348829 (B)</bold>.</p>
</caption>
<graphic xlink:href="av-67-12464-g004.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Molecular docking is investigated as a computational tool for virtually screening thousands of drug-like candidates for their affinity toward a specific molecular target, provided that the structure of the target protein is available. Molecular docking serves as the foundation for the structure-based drug design (SBDD) process. It is a fast, cost-effective, and simplified computational tool for predicting the scores associated with the association of putative ligand molecules and the target protein of interest. The obtained docking score offers a basic result for the discovery of leading compounds among the collection and may be taken into consideration for drug development plans (<xref ref-type="bibr" rid="B33">Wang and Zhu, 2016</xref>). When combined with results from experimental research, molecular docking-based virtual screening may aid in the process of rational medication design and development (<xref ref-type="bibr" rid="B27">Sethi et al., 2019</xref>).</p>
<p>With the thorough virtual screening procedure, molecular dynamics simulation also attracted a lot of attention in the search for potential hit compounds. (<xref ref-type="bibr" rid="B10">Ganesan et al., 2017</xref>). The most important feature of using molecular dynamics simulation in drug discovery pipelines is that it offers dynamic structural data on interactions between ligands and target receptors with a collection of complexes conformations (<xref ref-type="bibr" rid="B11">Gioia et al., 2017</xref>; <xref ref-type="bibr" rid="B26">Saurabh et al., 2020</xref>). According to current trends, molecular docking combined with molecular dynamics simulation is being actively studied to confirm potential interactions between ligand and receptor, which helps develop effective drug candidates.</p>
<p>For many decades, ingredients derived from plants have been thought to be the most explored drug candidates. It is possible to assess the potential use of plant-based metabolites with antiviral activity in the treatment of SARS-CoV-2 infections (<xref ref-type="bibr" rid="B3">Bhuiyan et al., 2020</xref>; <xref ref-type="bibr" rid="B16">Kumar Verma et al., 2021</xref>). In this context, it is crucial to use computational techniques to discover plant-derived phytochemicals that have an inhibitory effect on SARS-CoV-2 infections. For example, Hesperidin, Theaflavin, Biorobin (<xref ref-type="bibr" rid="B22">Peele et al., 2020</xref>); Rutin, (<xref ref-type="bibr" rid="B5">Das et al., 2021</xref>); Andrographolide (<xref ref-type="bibr" rid="B6">Enmozhi et al., 2021</xref>); Asiatic acid, Avicularin Guaijaverin, Chrysanthemin (<xref ref-type="bibr" rid="B2">Amin et al., 2021</xref>); and Hypericin (<xref ref-type="bibr" rid="B24">Pitsillou et al.,2020</xref>) have been screened as potential therapeutic drugs for 3CL<sup>pro</sup> of SARS-CoV-2 by SBDD, and some of which have had protease inhibition activity demonstrated <italic>in vitro</italic> experiments.</p>
<p>SARS-CoV-3CL<sup>pro</sup> consists of 306 amino acids and functionally inhibits replicase precursor polyproteins; further preventing COVID-19 gene expression and replication. There are three domains in the structure of 3CL<sup>pro</sup>, in which 8-101 residues form domain-I, 102-184 residues form domain-II with six-stranded anti-parallel &#x3b2;-barrel, and 201-303 residues form domain-III, which encompasses five a-helices grouped into the anti-parallel globular cluster and is linked to Domain-II by a long loop region (residues 185-200). Firstly, we identified the active pocket of the 3CL<sup>pro</sup>, which lies in a cleft between Domain-I and II and has a Cys145-His41 catalytic dyad that recognizes P1 Gln and P2 Leu/Met/Phe/Val as substrates, based on the binding site of the known standard inhibitor X77 named N-(4-tert-butylphenyl)-N-[(1R)-2-(cyclohexylamino)-2-oxo-1-(yridine-3-yl)ethyl]-1H-imidazole-4-carbox amide. In this study, we targeted the SARS-CoV-3CL<sup>pro</sup>; rapidly high-throughput virtual screening was performed to obtain the noncovalent SARS-CoV-2 3CL<sup>pro</sup> inhibitor from a natural product compounds database that includes 407270 natural products. In the subsequent virtual screening, we used X77 as a positive control and screened star-hits with -CDOCKER scores higher than X77. Amino acids including PHE140, GLN189, GLY143, GLU166, THR190, CYS145, and HIS163 were reported to be crucial in the inhibition process of M<sup>pro</sup> through hydrogen bonding, which was also verified in the results of our study (<xref ref-type="bibr" rid="B14">Jin et al., 2020</xref>). <xref ref-type="bibr" rid="B12">Gyebi et al. (2021)</xref> identified the importance of CYS145 and HIS41 as conserved catalytic dyad residues of SARS-CoV-2 Mpro. Interestingly, compounds <bold>CNP0348829</bold> and <bold>CNP0474002</bold> interacted with one of the two amino acids by hydrogen bond, and these interactions were also monitored in molecular dynamics simulations for the ligand-receptor complexes. According to the above analysis, we suggest that <bold>CNP0348829</bold> and <bold>CNP0474002</bold> could be potential inhibitors of 3CL<sup>pro</sup>. Nevertheless, further experiments are needed for activity validation in the future.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>Phytochemical screening <italic>in silico</italic> is especially alluring since it can digitally screen hundreds of compounds in a certain amount of time and examine the possibility of drug-like molecules. In this study, we performed structure-based virtual screening from a natural products library containing 407270 phytochemicals/traditional Chinese medicinal compounds, based on the crystal structures of the 3CL<sup>pro</sup> as an attractive target for small-molecule oral therapeutics for treating COVID-19. Through layers of virtual screening, <bold>CNP0348829</bold> and <bold>CNP0474002</bold>, as two selected star-hits, are promising as clinical candidate compounds for the treatment of SARS-CoV-2. Further experimental studies are suggested to check the possible preclinical and clinical efficacy of <bold>CNP0348829</bold> and <bold>CNP0474002</bold> for the prevention and treatment of COVID-19.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<fn-group>
<fn id="fn1">
<label>1</label>
<p>
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---14-december-2022">https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---14-december-2022</ext-link>
</p>
</fn>
<fn id="fn2">
<label>2</label>
<p>
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/who-expert-meeting-on-evaluation-of-traditional-chinese-medicine-in-the-treatment-of-covid-19">https://www.who.int/publications/m/item/who-expert-meeting-on-evaluation-of-traditional-chinese-medicine-in-the-treatment-of-covid-19</ext-link>
</p>
</fn>
<fn id="fn3">
<label>3</label>
<p>
<ext-link ext-link-type="uri" xlink:href="https://coconut.naturalproducts.net/">https://coconut.naturalproducts.net/</ext-link>
</p>
</fn>
<fn id="fn4">
<label>4</label>
<p>
<ext-link ext-link-type="uri" xlink:href="https://www.pdbus.org/">https://www.pdbus.org/</ext-link>
</p>
</fn>
<fn id="fn5">
<label>5</label>
<p>
<ext-link ext-link-type="uri" xlink:href="https://www.deshawresearch.com/downloads/download_desmond.cgi/">https://www.deshawresearch.com/downloads/download_desmond.cgi/</ext-link>
</p>
</fn>
<fn id="fn6">
<label>6</label>
<p>
<ext-link ext-link-type="uri" xlink:href="http://lmmd.ecust.edu.cn/admetsar2/">http://lmmd.ecust.edu.cn/admetsar2/</ext-link>
</p>
</fn>
<fn id="fn7">
<label>7</label>
<p>
<ext-link ext-link-type="uri" xlink:href="https://www.swissadme.ch/">https://www.swissadme.ch</ext-link>
</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adcock</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>McCammon</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Molecular dynamics: Survey of methods for simulating the activity of proteins</article-title>. <source>Chem. Rev.</source> <volume>106</volume> (<issue>5</issue>), <fpage>1589</fpage>&#x2013;<lpage>1615</lpage>. <pub-id pub-id-type="doi">10.1021/cr040426m</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amin</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gayen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jha</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors</article-title>. <source>J. Biomol. Struct. Dyn.</source> <volume>39</volume> (<issue>13</issue>), <fpage>4764</fpage>&#x2013;<lpage>4773</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1780946</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhuiyan</surname>
<given-names>F. R.</given-names>
</name>
<name>
<surname>Howlader</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Raihan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hasan</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Plants metabolites: possibility of natural therapeutics against the COVID-19 pandemic</article-title>. <source>Front. Med. (Lausanne)</source> <volume>7</volume>, <fpage>444</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2020.00444</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Michielin</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Zoete</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>42717</fpage>. <pub-id pub-id-type="doi">10.1038/srep42717</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sarmah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lyndem</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singha Roy</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study</article-title>. <source>J. Biomol. Struct. Dyn.</source> <volume>39</volume> (<issue>9</issue>), <fpage>3347</fpage>&#x2013;<lpage>3357</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1763201</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enmozhi</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Raja</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sebastine</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: An <italic>in silico</italic> approach</article-title>. <source>J. Biomol. Struct. Dyn.</source> <volume>39</volume> (<issue>9</issue>), <fpage>3092</fpage>&#x2013;<lpage>3098</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1760136</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fadaka</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Aruleba</surname>
<given-names>R. T.</given-names>
</name>
<name>
<surname>Sibuyi</surname>
<given-names>N. R. S.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Madiehe</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: A computational-aided approach</article-title>. <source>J. Biomol. Struct. Dyn.</source> <volume>40</volume> (<issue>8</issue>), <fpage>3416</fpage>&#x2013;<lpage>3427</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1847197</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fadaka</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Sibuyi</surname>
<given-names>N. R. S.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Madiehe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Development of effective therapeutic molecule from natural sources against coronavirus protease</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>17</issue>), <fpage>9431</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22179431</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gahlawat</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sandhu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>I. P.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Structure-based virtual screening to discover potential lead molecules for the SARS-CoV-2 main protease</article-title>. <source>J. Chem. Inf. Model</source> <volume>60</volume> (<issue>12</issue>), <fpage>5781</fpage>&#x2013;<lpage>5793</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00546</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ganesan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Coote</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Barakat</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Molecular dynamics-driven drug discovery: Leaping forward with confidence</article-title>. <source>Drug Discov. Today</source> <volume>22</volume> (<issue>2</issue>), <fpage>249</fpage>&#x2013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2016.11.001</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gioia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bertazzo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Recanatini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Masetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cavalli</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Dynamic docking: a paradigm shift in computational drug discovery</article-title>. <source>Molecules</source> <volume>22</volume> (<issue>11</issue>), <fpage>2029</fpage>. <pub-id pub-id-type="doi">10.3390/molecules22112029</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gyebi</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Ogunro</surname>
<given-names>O. B.</given-names>
</name>
<name>
<surname>Adegunloye</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Ogunyemi</surname>
<given-names>O. M.</given-names>
</name>
<name>
<surname>Afolabi</surname>
<given-names>S. O.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): An <italic>in silico</italic> screening of alkaloids and terpenoids from african medicinal plants</article-title>. <source>J. Biomol. Struct. Dyn.</source> <volume>39</volume> (<issue>9</issue>), <fpage>3396</fpage>&#x2013;<lpage>3408</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1764868</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Youn</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Traditional Chinese Medicine (TCM) in the treatment of covid-19 and other viral infections: efficacies and mechanisms</article-title>. <source>Pharmacol. Ther.</source> <volume>225</volume>, <fpage>107843</fpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107843</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A comprehensive application: molecular docking and network pharmacology for the prediction of bioactive constituents and elucidation of mechanisms of action in component-based Chinese medicine</article-title>. <source>Comput. Biol. Chem.</source> <volume>90</volume>, <fpage>107402</fpage>. <pub-id pub-id-type="doi">10.1016/j.compbiolchem.2020.107402</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors</article-title>. <source>Nature</source> <volume>582</volume> (<issue>7811</issue>), <fpage>289</fpage>&#x2013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kruth</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mercelis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Van Vaerenbergh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Froyen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rombouts</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Binding mechanisms in selective laser sintering and selective laser melting</article-title>. <source>Rapid Prototyp. J.</source> <volume>11</volume> (<issue>1</issue>), <fpage>26</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1108/13552540510573365</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar Verma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Goswami</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Camps</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sekar</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies</article-title>. <source>Biomed. Pharmacother.</source> <volume>137</volume>, <fpage>111356</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.111356</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z. Y.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Molecular dynamics simulation of &#x3b2;-adrenoceptors and their coupled G proteins</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source> <volume>23</volume> (<issue>14</issue>), <fpage>6346</fpage>&#x2013;<lpage>6351</lpage>. <pub-id pub-id-type="doi">10.26355/eurrev_201907_18458</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipinski</surname>
<given-names>C. A.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Lead- and drug-like compounds: The rule-of-five revolution</article-title>. <source>Drug Discov. Today Technol.</source> <volume>1</volume> (<issue>4</issue>), <fpage>337</fpage>&#x2013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2004.11.007</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jha</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Hazra</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Plant products as inhibitors of coronavirus 3CL protease</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>583387</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.583387</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Valsalan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nazeem</surname>
<given-names>P. A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Molecular docking studies of phytochemicals from Phyllanthus niruri against Hepatitis B DNA Polymerase</article-title>. <source>Bioinformation</source> <volume>11</volume> (<issue>9</issue>), <fpage>426</fpage>&#x2013;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.6026/97320630011426</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okimoto</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Futatsugi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fuji</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Suenaga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morimoto</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yanai</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>High-performance drug discovery: Computational screening by combining docking and molecular dynamics simulations</article-title>. <source>PLoS Comput. Biol.</source> <volume>5</volume> (<issue>10</issue>), <fpage>e1000528</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1000528</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peele</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Potla Durthi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Srihansa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Krupanidhi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ayyagari</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Babu</surname>
<given-names>D. J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: a computational study</article-title>. <source>Inf. Med. Unlocked</source> <volume>19</volume>, <fpage>100345</fpage>. <pub-id pub-id-type="doi">10.1016/j.imu.2020.100345</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rastelli</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Molecular docking: shifting paradigms in drug discovery</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume> (<issue>18</issue>), <fpage>4331</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20184331</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitsillou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Karagiannis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ververis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Darmawan</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Interaction of small molecules with the SARS-CoV-2 main protease <italic>in silico</italic> and <italic>in vitro</italic> validation of potential lead compounds using an enzyme-linked immunosorbent assay</article-title>. <source>Comput. Biol. Chem.</source> <volume>89</volume>, <fpage>107408</fpage>. <pub-id pub-id-type="doi">10.1016/j.compbiolchem.2020.107408</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahebnasagh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Avan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Saghafi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mojtahedzadeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sadremomtaz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arasteh</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Pharmacological treatments of COVID-19</article-title>. <source>Pharmacol. Rep.</source> <volume>72</volume> (<issue>6</issue>), <fpage>1446</fpage>&#x2013;<lpage>1478</lpage>. <pub-id pub-id-type="doi">10.1007/s43440-020-00152-9</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Saurabh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sivakumar</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Perumal</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). &#x201c;<article-title>Molecular dynamics simulations in drug discovery and drug delivery</article-title>,&#x201d; in <source>Integrative nanomedicine for new therapies</source> (<publisher-loc>Berlin, Germany</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>275</fpage>&#x2013;<lpage>301</lpage>.</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sethi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sasikala</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Alvala</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Molecular docking in modern drug discovery: principles and recent applications</article-title>. <source>Drug Discov. development-new Adv.</source> <volume>2</volume>, <fpage>1</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.5772/intechopen.85991</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srivastava</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Seth</surname>
<given-names>P. K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>A molecular dynamics simulation study of the ACE2 receptor with screened natural inhibitors to identify novel drug candidate against COVID-19</article-title>. <source>PeerJ</source> <volume>9</volume>, <fpage>e11171</fpage>. <pub-id pub-id-type="doi">10.7717/peerj.11171</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tahir Ul Qamar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alqahtani</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Alamri</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L. L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants</article-title>. <source>J. Pharm. Anal.</source> <volume>10</volume> (<issue>4</issue>), <fpage>313</fpage>&#x2013;<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.009</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ullrich</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nitsche</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The SARS-CoV-2 main protease as drug target</article-title>. <source>Bioorg Med. Chem. Lett.</source> <volume>30</volume> (<issue>17</issue>), <fpage>127377</fpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127377</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Unoh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Uehara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakahara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nobori</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamatsu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19</article-title>. <source>J. Med. Chem.</source> <volume>65</volume> (<issue>9</issue>), <fpage>6499</fpage>&#x2013;<lpage>6512</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c00117</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Horby</surname>
<given-names>P. W.</given-names>
</name>
<name>
<surname>Hayden</surname>
<given-names>F. G.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>G. F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A novel coronavirus outbreak of global health concern</article-title>. <source>Lancet</source> <volume>395</volume> (<issue>10223</issue>), <fpage>470</fpage>&#x2013;<lpage>473</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30185-9</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Molecular docking for drug discovery and development: A widely used approach but far from perfect</article-title>. <source>Future Med. Chem.</source> <volume>8</volume> (<issue>14</issue>), <fpage>1707</fpage>&#x2013;<lpage>1710</lpage>. <pub-id pub-id-type="doi">10.4155/fmc-2016-0143</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="book">
<collab>WHO Team</collab> (<year>2022</year>). <source>WHO expert meeting on evaluation of traditional Chinese medicine in the treatment of COVID-19</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>, <fpage>4</fpage>&#x2013;<lpage>17</lpage>.</citation>
</ref>
<ref id="B35">
<citation citation-type="book">
<collab>World Health Organization</collab> (<year>2022</year>). <source>Weekly epidemiological update on COVID-19-28 December 2022</source>. <comment>[EB/OL]. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---14-december-2022">https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---14-december-2022</ext-link> (Accessed December 14, 2022)</comment>.</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>C. L.</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Vieth</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm</article-title>. <source>J. Comput. Chem.</source> <volume>24</volume> (<issue>13</issue>), <fpage>1549</fpage>&#x2013;<lpage>1562</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.10306</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties</article-title>. <source>Bioinformatics</source> <volume>35</volume> (<issue>6</issue>), <fpage>1067</fpage>&#x2013;<lpage>1069</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty707</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhuang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Chinese patent medicines in the treatment of coronavirus disease 2019 (COVID-19) in China</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>1066</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.01066</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>